<DOC>
	<DOCNO>NCT02603575</DOCNO>
	<brief_summary>Pneumocystis Pneumonia increase Immunocompromised Non-HIV Infected Patients . The effect safety caspofungin corticosteroid certain population . All Immunocompromised Non-HIV patient respiratory failure randomize caspofungin non-caspofungin group corticosteroid non-steroids group . The major outcome 28 day mortality , second outcome time respiratory rate decrease le 25 breath per minute , body temperature low 37.3℃ .</brief_summary>
	<brief_title>Effects Safety Caspofungin Corticosteroids Pneumocystis Pneumonia Non-HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Sulfanilamide</mesh_term>
	<mesh_term>Sulfanilamides</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Immunocompromised NonHIV Infected Patients Partial arterial O2 pressure ( PaO2 ) /FiO2≤300mmHg Diagnosed Pneumocystis Pneumonia young 16 year old severe organ failure allergic sulfanilamide , caspofungin corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Caspofungin</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>Pneumocystis Pneumonia</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Non-HIV</keyword>
	<keyword>respiratory failure</keyword>
</DOC>